4 results

123 Metabolically healthy obesity: it is time to consider its dynamic changes
Yun Kyung Cho, Chang Hee Jung
KMSID: 1516079549   Cardiovasc Prev Pharmacother. 2022;4(4):123-131.   Published online 2022 October 24    DOI: http://dx.doi.org/10.36011/cpp.2022.4.e19
      
132 The crosstalk between insulin resistance and nonalcoholic fatty liver disease/metabolic dysfunction-associated fatty liver disease: a culprit or a consequence?
Dae-Jeong Koo, Won-Young Lee
KMSID: 1516079547   Cardiovasc Prev Pharmacother. 2022;4(4):132-141.   Published online 2022 October 20    DOI: http://dx.doi.org/10.36011/cpp.2022.4.e17
      
142 The effects and side effects of liraglutide as a treatment for obesity
Jeonghoon Ha, Jin Yu, Joonyub Lee, Hun-Sung Kim
KMSID: 1516079546   Cardiovasc Prev Pharmacother. 2022;4(4):142-148.   Published online 2022 October 20    DOI: http://dx.doi.org/10.36011/cpp.2022.4.e18
      
149 Public awareness of cardiovascular disease prevention in Korea
Eunji Kim, Chan-Hee Jung, Eun-Jung Rhee, Junghyun Noh, Jae Hyuk Lee, Hun-Jun Park, Sungha Park, Sang-Hyun Ihm, Won-Young Lee, Hyeon Chang Kim
KMSID: 1516079548   Cardiovasc Prev Pharmacother. 2022;4(4):149-157.   Published online 2022 October 26    DOI: http://dx.doi.org/10.36011/cpp.2022.4.e20
      
Articles from Cardiovascular Prevention and Pharmacotherapy are provided here courtesy of Korean Society of Cardiovascular Disease Prevention; Korean Society of Cardiovascular Pharmacotherap